TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Return on equity 2016–2025
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
17.8%FY2025 · since FY2016: 1.0% → 17.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 17.8% | +48.3 pp |
| FY2024 | -30.5% | -23.1 pp |
| FY2023 | -7.4% | +23.9 pp |
| FY2022 | -31.3% | -35.4 pp |
| FY2021 | 4.1% | +43.9 pp |
| FY2020 | -39.8% | -32.6 pp |
| FY2019 | -7.2% | +7.5 pp |
| FY2018 | -14.6% | +79.1 pp |
| FY2017 | -93.7% | -94.7 pp |
| FY2016 | 1.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice